Literature DB >> 8849226

Susceptibilities of Bordetella pertussis strains to antimicrobial peptides.

R C Fernandez1, A A Weiss.   

Abstract

We examined the susceptibilities of Bordetella pertussis strains to several antimicrobial peptides by determining the concentration required to inhibit or kill 50% of the bacterial population. The peptides are ranked in decreasing potency as follows: cecropin B > cecropin A >> melittin > cecropin P1 > (ala8,13,18)-magainin II amide > mastoparan = defensin HNP1 > protamine > or = magainin II = magainin I. By using a radial diffusion assay to compare susceptibilities between strains, wild-type B. pertussis BP338 was more resistant than the avirulent bvg mutant strain BP347 and the brk mutant strain BPM2041 to killing by cecropin P1. In contrast, compared with the wild type, the avirulent BP347 strain was highly resistant to killing by protamine and defensin HNP1.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8849226      PMCID: PMC163258     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  23 in total

Review 1.  Antibacterial peptides: key components needed in immunity.

Authors:  H G Boman
Journal:  Cell       Date:  1991-04-19       Impact factor: 41.582

2.  Tracheal antimicrobial peptide, a cysteine-rich peptide from mammalian tracheal mucosa: peptide isolation and cloning of a cDNA.

Authors:  G Diamond; M Zasloff; H Eck; M Brasseur; W L Maloy; C L Bevins
Journal:  Proc Natl Acad Sci U S A       Date:  1991-05-01       Impact factor: 11.205

3.  Ultrasensitive assays for endogenous antimicrobial polypeptides.

Authors:  R I Lehrer; M Rosenman; S S Harwig; R Jackson; P Eisenhauer
Journal:  J Immunol Methods       Date:  1991-03-21       Impact factor: 2.303

4.  Use of the promoter fusion transposon Tn5 lac to identify mutations in Bordetella pertussis vir-regulated genes.

Authors:  A A Weiss; A R Melton; K E Walker; C Andraos-Selim; J J Meidl
Journal:  Infect Immun       Date:  1989-09       Impact factor: 3.441

5.  Pertussis toxin and extracytoplasmic adenylate cyclase as virulence factors of Bordetella pertussis.

Authors:  A A Weiss; E L Hewlett; G A Myers; S Falkow
Journal:  J Infect Dis       Date:  1984-08       Impact factor: 5.226

6.  Naturally crystalline porin in the outer membrane of Bordetella pertussis.

Authors:  M Kessel; M J Brennan; B L Trus; M E Bisher; A C Steven
Journal:  J Mol Biol       Date:  1988-09-05       Impact factor: 5.469

Review 7.  The barrier function of the gram-negative envelope.

Authors:  L Leive
Journal:  Ann N Y Acad Sci       Date:  1974-05-10       Impact factor: 5.691

8.  Molecular cloning and characterization of protective outer membrane protein P.69 from Bordetella pertussis.

Authors:  I G Charles; G Dougan; D Pickard; S Chatfield; M Smith; P Novotny; P Morrissey; N F Fairweather
Journal:  Proc Natl Acad Sci U S A       Date:  1989-05       Impact factor: 11.205

9.  Tracheal colonization factor: a Bordetella pertussis secreted virulence determinant.

Authors:  T M Finn; L A Stevens
Journal:  Mol Microbiol       Date:  1995-05       Impact factor: 3.501

10.  Antibacterial peptides from pig intestine: isolation of a mammalian cecropin.

Authors:  J Y Lee; A Boman; C X Sun; M Andersson; H Jörnvall; V Mutt; H G Boman
Journal:  Proc Natl Acad Sci U S A       Date:  1989-12       Impact factor: 11.205

View more
  10 in total

1.  D-alanine modification of a protease-susceptible outer membrane component by the Bordetella pertussis dra locus promotes resistance to antimicrobial peptides and polymorphonuclear leukocyte-mediated killing.

Authors:  Neetu Kumra Taneja; Tridib Ganguly; Lauren O Bakaletz; Kimberly J Nelson; Purnima Dubey; Leslie B Poole; Rajendar Deora
Journal:  J Bacteriol       Date:  2013-09-06       Impact factor: 3.490

2.  Bordetella pertussis lipid A glucosamine modification confers resistance to cationic antimicrobial peptides and increases resistance to outer membrane perturbation.

Authors:  Nita R Shah; Robert E W Hancock; Rachel C Fernandez
Journal:  Antimicrob Agents Chemother       Date:  2014-05-27       Impact factor: 5.191

Review 3.  Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies.

Authors:  Seema Mattoo; James D Cherry
Journal:  Clin Microbiol Rev       Date:  2005-04       Impact factor: 26.132

4.  The lipopolysaccharide of Bordetella bronchiseptica acts as a protective shield against antimicrobial peptides.

Authors:  A Banemann; H Deppisch; R Gross
Journal:  Infect Immun       Date:  1998-12       Impact factor: 3.441

5.  Strain-dependent role of BrkA during Bordetella pertussis infection of the murine respiratory tract.

Authors:  Kelly D Elder; Eric T Harvill
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

6.  Highly attenuated Bordetella pertussis strain BPZE1 as a potential live vehicle for delivery of heterologous vaccine candidates.

Authors:  Si Ying Ho; Shi Qian Chua; Damian G W Foo; Camille Locht; Vincent T Chow; Chit Laa Poh; Sylvie Alonso
Journal:  Infect Immun       Date:  2007-10-22       Impact factor: 3.441

7.  The host defense peptide beta-defensin 1 confers protection against Bordetella pertussis in newborn piglets.

Authors:  Shokrollah Elahi; Rachelle M Buchanan; Sam Attah-Poku; Hugh G G Townsend; Lorne A Babiuk; Volker Gerdts
Journal:  Infect Immun       Date:  2006-04       Impact factor: 3.441

8.  Characterization of human bactericidal antibodies to Bordetella pertussis.

Authors:  A A Weiss; P S Mobberley; R C Fernandez; C M Mink
Journal:  Infect Immun       Date:  1999-03       Impact factor: 3.441

9.  Functional and structural characteristics of anticancer peptide Pep27 analogues.

Authors:  Dong Gun Lee; Kyung-Soo Hahm; Yoonkyung Park; Hai-Young Kim; Weontae Lee; Sung-Chul Lim; Youn-Kyung Seo; Cheol-Hee Choi
Journal:  Cancer Cell Int       Date:  2005-07-11       Impact factor: 5.722

Review 10.  Rediscovering Pertussis.

Authors:  Manuela Zlamy
Journal:  Front Pediatr       Date:  2016-06-08       Impact factor: 3.418

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.